The University of Texas Health Science Center at San Antonio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, The University of Texas Health Science Center at San Antonio sits in the top decile of US sponsors by registered trial count (#94 of 15,742 sponsors by registered trial count).
The University of Texas Health Science Center at San Antonio: 378 sponsored US clinical trials, 77 recruiting.
The University of Texas Health Science Center at San Antonio sponsors 378 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 264 completed. 41 of these trials are in Phase 3-4 (later-stage) and 124 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes, with 13 trials.
Top-decile sponsor footprint
The University of Texas Health Science Center at San Antonio ranks in the top decile of sponsors by registered trial count (#94 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
264 of 284 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
378 total, page 4 of 8
Clinical Trial to Decrease Length of Stay in Infants With Neonatal Abstinence Syndrome With an Exclusive Human Milk Diet
NCT04508348
Personalized Behavioral Nutrition Intervention in Older AAs With T2D
NCT04533659
Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity
NCT04590040
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
NCT04401904
Effect of Gender Affirming Hormone Therapy on Glucose Metabolism
NCT04515472
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
NCT04200911
Radiation Oncology Patient Medical Physics Intervention Study
NCT04362306
Retention of Nasoenteric Feeding Tubes in Pediatric Patients Using a Nasal Bridle
NCT04621734
Senolytic Therapy to Modulate Progression of Alzheimer's Disease
NCT04063124
RAPA-Keloid Study of Keloid Regression
NCT04049552
Holistic Intervention for Cancer Survivors
NCT06749938
Antibiotic Selection Using Next Generation Sequencing vs Urine Culture
NCT04404855
Predicting Treatment Outcomes With Intensive Outpatient Treatment for PTSD
NCT04307498
Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
NCT03995706
Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes
NCT04440449
Imipramine on ER+ve and Triple Negative Breast Cancer
NCT03122444
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
NCT02981966
Cognitive Adaption Training-Effectiveness in Real-world Settings and Mechanism of Action (CAT-EM)
NCT03829280
Reducing the Abuse of Opioids in Drug Users
NCT03837860
The South Texas Aging Registry and Repository
NCT05835388
Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury
NCT04280965
Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy
NCT03799523
Impact of Metformin on Immunity
NCT03713801
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
NCT03560323
Network Dysregulation Among Individuals With Comorbid Tinnitus and PTSD
NCT03702166
Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron
NCT03612401
Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma
NCT03458546
Empagliflozin and Hepatic Glucose Metabolism
NCT03193684
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
NCT03331289
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism
NCT04300049
Optimal Feeding Tube Placement
NCT04241146
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
NCT02981069
The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition
NCT02942888
Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy
NCT03329131
Acceptance and Commitment Therapy for Chronic Pain in Integrated Primary Care
NCT04978961
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
NCT02984644
Treatment of Depression With Connectivity Guided Robotically Delivered rTMS
NCT02802293
Image-guided, Robotically Delivered Transcranial Magnetic Stimulation Treatment for Combat-Related Post-Traumatic Stress Disorder
NCT02853032
Reducing the Abuse Liability of Prescription Opioids
NCT04587115
Breast, Omega 3 Free Fatty Acid, Ph 0
NCT02996240
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
NCT03032484
Leveraging Transdermal Alcohol Monitoring to Reduce Drinking Among DWI Defendants
NCT03638596
TRanslesIonal Assessment of Gradients During Endovascular Therapy
NCT03163199
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
NCT03037437
Project Remission: Maximizing Outcomes With Intensive Treatments for Combat-Related PTSD
NCT03529435
Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer
NCT03397030
Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy
NCT03040050
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
NCT02911792
Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
NCT03064568
EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
NCT02618343
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 79 |
| Phase 2 | 45 |
| Phase 3 | 8 |
| Phase 4 | 33 |
Therapeutic Areas
What is open in the The University of Texas Health Science Center at San Antonio pipeline
77 recruiting of 378 indexed (20% open); 264 completed (70%).
Phase mix: 41 late (III/IV) vs 124 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The University of Texas Health Science Center at San Antonio: open-pipeline peers nationwide
Peers matched on 378 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
The University of Texas Health Science Center at San Antonio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 378 trials (± recruiting share)
- Northwell Health · 370 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
Sponsors near 20% open enrollment (± trial volume)
- M.D. Anderson Cancer Center · 20% recruiting · 2,692 trials
- University of Georgia · 20% recruiting · 59 trials
- University of Houston · 20% recruiting · 64 trials
- Florida International University · 20% recruiting · 89 trials
Related
What to do with this The University of Texas Health Science Center at San Antonio page
378 registered trials is a research-attention snapshot, not an endorsement of The University of Texas Health Science Center at San Antonio or any single study.
- 77 of The University of Texas Health Science Center at San Antonio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes is the condition The University of Texas Health Science Center at San Antonio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. The University of Texas Health Science Center at San Antonio pipeline card: 378 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.